Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial
World Journal of Urology · 2024
DOI: 10.1007/s00345-024-05025-x ↗Kurz gefasst
Leserbrief in der Zeitschrift World Journal of Urology, 2024. Verfasst von Rong Dai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Chengdu Center for Disease Control and Prevention, Chengdu, 610041, China. Hauptthemen laut MEDLINE: Acetanilides, Cross-Over Studies, Thiazoles, Urinary Bladder, Overactive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chengdu Center for Disease Control and Prevention, Chengdu, 610041, China.
- Department of Pediatric Surgery, School of Medicine, Chengdu Women's and Children's Central Hospital, University of Electronic Science and Technology of China, Chengdu, 611731, China. 15882420198@163.com.
Zitieren
APA
Dai, R., & Deng, C. (2024). Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World Journal of Urology. https://doi.org/10.1007/s00345-024-05025-x
Vancouver
Dai R, Deng C. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World Journal of Urology. 2024. doi:10.1007/s00345-024-05025-x
BibTeX
@article{Dai2024,
author = {Dai, Rong and Deng, Changkai},
title = {Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial},
journal = {World Journal of Urology},
year = {2024},
doi = {10.1007/s00345-024-05025-x}
}
EUVIMED